Lymphangitis carcinomatosa: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 19: | Line 19: | ||
*The [[pathogenesis]] is also characterized by retrograde [[Spread of the cancer|spread]] into [[lymphatics]] from the [[mediastinal]] and [[hilar]] [[lymph nodes]] in the [[lungs]]. | *The [[pathogenesis]] is also characterized by retrograde [[Spread of the cancer|spread]] into [[lymphatics]] from the [[mediastinal]] and [[hilar]] [[lymph nodes]] in the [[lungs]]. | ||
*There are no specific [[genetic]] [[mutations]] associated with the [[development]] of [[lymphangitis]] carcinomatosa. | *There are no specific [[genetic]] [[mutations]] associated with the [[development]] of [[lymphangitis]] carcinomatosa. | ||
*On [[gross pathology]], characteristic findings of [[lymphangitis]] carcinomatosa include:<ref name="lymph">Lymphangitis carcinomatosa. Libre Pathology. https://librepathology.org/wiki/Pulmonary_lymphangitic_carcinomatosis | *On [[gross pathology]], characteristic findings of [[lymphangitis]] carcinomatosa include:<ref name="lymph">Lymphangitis carcinomatosa. Libre Pathology. https://librepathology.org/wiki/Pulmonary_lymphangitic_carcinomatosis</ref> | ||
:*No remarkable findings | :*No remarkable findings | ||
*On [[microscopic]] [[histopathological]] [[analysis]], characteristic findings of [[lymphangitis]] carcinomatosa include:<ref name="lymph">Lymphangitis carcinomatosa. Libre Pathology. https://librepathology.org/wiki/Pulmonary_lymphangitic_carcinomatosis Accesed on April 29, 2016</ref> | *On [[microscopic]] [[histopathological]] [[analysis]], characteristic findings of [[lymphangitis]] carcinomatosa include:<ref name="lymph">Lymphangitis carcinomatosa. Libre Pathology. https://librepathology.org/wiki/Pulmonary_lymphangitic_carcinomatosis Accesed on April 29, 2016</ref> | ||
| Line 25: | Line 25: | ||
==Causes== | ==Causes== | ||
*Common [[causes]] of lymphangitis carcinomatosa include:<ref name="lymph">Lymphangitis carcinomatosa. Libre Pathology. https://librepathology.org/wiki/Pulmonary_lymphangitic_carcinomatosis | *Common [[causes]] of lymphangitis carcinomatosa include:<ref name="lymph">Lymphangitis carcinomatosa. Libre Pathology. https://librepathology.org/wiki/Pulmonary_lymphangitic_carcinomatosis</ref> | ||
**[[Breast cancer]] (most common) | **[[Breast cancer]] (most common) | ||
**[[Lung cancer]] | **[[Lung cancer]] | ||
| Line 44: | Line 44: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
*[[Lymphangitis]] carcinomatosa is a [[rare]] [[disease]]. | *[[Lymphangitis]] carcinomatosa is a [[rare]] [[disease]]. | ||
*The [[prevalence]] of [[lymphangitis]] carcinomatosa is approximately 0.03 per 100,000 individuals worldwide.<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis | *The [[prevalence]] of [[lymphangitis]] carcinomatosa is approximately 0.03 per 100,000 individuals worldwide.<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis</ref> | ||
===Age=== | ===Age=== | ||
*[[Patients]] of all [[age]] groups may [[Development|develop]] [[lymphangitis]] carcinomatosa. | *[[Patients]] of all [[age]] groups may [[Development|develop]] [[lymphangitis]] carcinomatosa. | ||
*[[Lymphangitis]] carcinomatosa is more commonly observed among [[patients]] [[Age|aged]] 40–49 [[Year|years]] old.<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis | *[[Lymphangitis]] carcinomatosa is more commonly observed among [[patients]] [[Age|aged]] 40–49 [[Year|years]] old.<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis</ref> | ||
*[[Lymphangitis]] carcinomatosa is more commonly observed among middle [[Age|aged]] [[Adult|adults]]. | *[[Lymphangitis]] carcinomatosa is more commonly observed among middle [[Age|aged]] [[Adult|adults]]. | ||
| Line 59: | Line 59: | ||
==Risk Factors== | ==Risk Factors== | ||
*Common [[risk factors]] in the [[development]] of [[lymphangitis]] carcinomatosa include:<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis | *Common [[risk factors]] in the [[development]] of [[lymphangitis]] carcinomatosa include:<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis</ref> | ||
:*Personal [[History and Physical examination|history]] of [[cancer]] | :*Personal [[History and Physical examination|history]] of [[cancer]] | ||
:*Preexistent [[malignant]] [[cancer]] | :*Preexistent [[malignant]] [[cancer]] | ||
| Line 99: | Line 99: | ||
===Imaging Findings=== | ===Imaging Findings=== | ||
*[[Computed tomography]] is the [[imaging]] [[modality]] of choice for [[lymphangitis]] carcinomatosa.<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis | *[[Computed tomography]] is the [[imaging]] [[modality]] of choice for [[lymphangitis]] carcinomatosa.<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis</ref> | ||
*The most important feature about [[CT scan]] is the detection of peripheral and central changes. | *The most important feature about [[CT scan]] is the detection of peripheral and central changes. | ||
*On [[CT]], characteristic findings of [[lymphangitis]] carcinomatosa include:<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis | *On [[CT]], characteristic findings of [[lymphangitis]] carcinomatosa include:<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis</ref> | ||
:*Subpleural [[nodules]], and thickening on the interlobar [[fissures]] | :*Subpleural [[nodules]], and thickening on the interlobar [[fissures]] | ||
:*[[Pleural effusion]] | :*[[Pleural effusion]] | ||
| Line 112: | Line 112: | ||
== Treatment == | == Treatment == | ||
=== Medical Therapy === | === Medical Therapy === | ||
*The mainstay [[therapy]] for [[lymphangitis]] carcinomatosa is [[systemic]] [[chemotherapy]] ([[chemotherapeutic]] [[Chemotherapy regimens|regimen]] depends on the [[tumor]] [[histology]]).<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis | *The mainstay [[therapy]] for [[lymphangitis]] carcinomatosa is [[systemic]] [[chemotherapy]] ([[chemotherapeutic]] [[Chemotherapy regimens|regimen]] depends on the [[tumor]] [[histology]]).<ref name="radio">Lymphangitis carcinomatosa. Radiopedia. http://radiopaedia.org/articles/lymphangitic-carcinomatosis</ref> | ||
=== Surgery === | === Surgery === | ||
Revision as of 15:25, 28 May 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Swathi Venkatesan, M.B.B.S.[2]
Synonyms and keywords: Lymphangitis carcinomatosis; Pulmonary lymphangitic carcinomatosis
Overview
Lymphangitis carcinomatosa is an inflammation of the lymph vessels secondary to a malignancy. Lymphangitis carcinomatosa was first discovered by Gabriel Andral, a French pathologist, in 1829. The pathogenesis of lymphangitis carcinomatosa is characterized by the tumoral spread into the lymphatics, following hematogenous seeding of the lungs. The pathogenesis is also characterized by retrograde spread into lymphatics from the mediastinal and hilar lymph nodes in the lungs. Common causes of lymphangitis carcinomatosa include breast cancer (most common), lung cancer, colon cancer, stomach cancer, prostate cancer, cervical cancer, and thyroid cancer. Lymphangitis carcinomatosa is a rare disease. The prevalence of lymphangitis carcinomatosa is approximately 0.03 per 100,000 individuals worldwide. Lymphangitis carcinomatosa is more commonly observed among patients aged between 40 to 49 years old. Computed tomography is the imaging modality of choice for lymphangitis carcinomatosa. On CT, characteristic findings of lymphangitis carcinomatosa include subpleural nodules, thickening on the interlobar fissures, pleural effusion, and hilar and mediastinal nodal enlargement (40-50%). The mainstay therapy for lymphangitis carcinomatosa is systemic chemotherapy (chemotherapeutic regimen depends on the tumor histology).
Historical Perspective
- Lymphangitis carcinomatosa was first discovered by Gabriel Andral, a French pathologist, in 1829.
Classification
- There is no classification for lymphangitis carcinomatosa.
Pathophysiology
- The pathogenesis of lymphangitis carcinomatosa is characterized by the tumoral spread into the lymphatics, following hematogenous seeding of the lungs.
- The pathogenesis is also characterized by retrograde spread into lymphatics from the mediastinal and hilar lymph nodes in the lungs.
- There are no specific genetic mutations associated with the development of lymphangitis carcinomatosa.
- On gross pathology, characteristic findings of lymphangitis carcinomatosa include:[1]
- No remarkable findings
- On microscopic histopathological analysis, characteristic findings of lymphangitis carcinomatosa include:[1]
Causes
Differentiating Lymphangitis Carcinomatosa from Other Diseases
- Lymphangitis carcinomatosa must be differentiated from other diseases that cause thickened interlobular septae (on imaging finding), dyspnea, fatigue, and weight-loss, such as:
Epidemiology and Demographics
- Lymphangitis carcinomatosa is a rare disease.
- The prevalence of lymphangitis carcinomatosa is approximately 0.03 per 100,000 individuals worldwide.[2]
Age
- Patients of all age groups may develop lymphangitis carcinomatosa.
- Lymphangitis carcinomatosa is more commonly observed among patients aged 40–49 years old.[2]
- Lymphangitis carcinomatosa is more commonly observed among middle aged adults.
Gender
- Females are more commonly affected with lymphangitis carcinomatosa than males.
Race
- There is no racial predilection for lymphangitis carcinomatosa.
Risk Factors
- Common risk factors in the development of lymphangitis carcinomatosa include:[2]
Natural History, Complications and Prognosis
- The majority of patients with lymphangitis carcinomatosa are symptomatic at the time of diagnosis.
- Early clinical features include dyspnea, fatigue, and weight-loss.
- If left untreated, patients with lymphangitis carcinomatosa may progress to develop acute respiratory failure.
- Common complications of lymphangitis carcinomatosa include:
- Prognosis is generally poor, and the mean survival rate of patients after diagnosis of lymphangitis carcinomatosa is approximately 6 months.
Diagnosis
Symptoms
- Lymphangitis carcinomatosa is usually asymptomatic.
- Symptoms of lymphangitis carcinomatosa may include the following:[2]
- Hemoptysis
- Chronic coughing
- Chest pain
- Loss of appetite
- Fatigue
Physical Examination
- Patients with lymphangitis carcinomatosa usually appear pale and malnourished.
- Physical examination may be remarkable for:[2]
Auscultation
- Present pleural friction rub
- Present egophony
- Crackling or bubbling noises
- Present whispered pectoriloquy
- Decreased/absent breath sounds
Percussion
- Dull percussion
- Reduced chest expansion
Laboratory Findings
- There are no specific laboratory findings associated with lymphangitis carcinomatosa.
Imaging Findings
- Computed tomography is the imaging modality of choice for lymphangitis carcinomatosa.[2]
- The most important feature about CT scan is the detection of peripheral and central changes.
- On CT, characteristic findings of lymphangitis carcinomatosa include:[2]
- Subpleural nodules, and thickening on the interlobar fissures
- Pleural effusion
- Hilar and mediastinal nodal enlargement (40-50%)
- Relatively little destruction of overall lung architecture
- Involvement of the peripheral (interlobular septa) and central lymphatic system
- Distribution of changes is variable, but most are asymmetric and patchy
- Usually bilateral (may be unilateral especially in cases of lung and breast cancer)
Treatment
Medical Therapy
- The mainstay therapy for lymphangitis carcinomatosa is systemic chemotherapy (chemotherapeutic regimen depends on the tumor histology).[2]
Surgery
- Surgery is not recommended for patients with lymphangitis carcinomatosa.
Prevention
- There are no primary preventive measures available for lymphangitis carcinomatosa.
- Once diagnosed and successfully treated, patients with lymphangitis carcinomatosa are followed-up periodically.
- Follow-up testing may include respiratory function tests and disease progression monitorization.